U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07267247) titled 'Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer' on Nov. 25.
Brief Summary: This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.
Study Start Date: June 01, 2022
Study Type: OBSERVATIONAL
Condition:
Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
Drug-Related Side Effects and Adverse Reactions (MeSH Term)
Egfr Tyrosine Kinase Inhibitor
Cardiotoxicity
Intervention:
DRUG: ...